Raphael I.
- Country
- France
- Department
- Hematology
Research Overview
- Phase I/II Evaluation of Sulfasalazine, Idarubicin, and Cytarabine in Newly Diagnosed Non-Favorable Acute Myeloid Leukemia Patients Aged 60 and Above
- Phase II Evaluation of Azacitidine and Venetoclax Combination Therapy in Higher-Risk Chronic Myelomonocytic Leukemia Patients
- Phase 1 Multicenter Open-Label Study of REM-422, an MYB mRNA Degrader, in Relapsed/Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndromes
Data & Insights
Has run more than one trial at 9 of 24 partner sites.
Specializations
Hematologic Malignancies
This investigator specializes in treating advanced blood cancers, with particular emphasis on Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS). Their research encompasses both newly diagnosed and relapsed/refractory cases.
- Relapsed/Refractory AML
- Higher-Risk MDS
- Non-favorable AML in elderly patients
Their work includes investigation of novel therapeutic approaches for these challenging hematologic conditions.
Novel Therapeutic Combinations
The investigator focuses on developing innovative treatment combinations, including mRNA degraders and conventional chemotherapy modifications. Their research explores new therapeutic strategies for patients with limited treatment options.
- MYB mRNA degrader therapy
- Chemotherapy enhancement strategies
- Combined treatment approaches
Their work encompasses the evaluation of both established and experimental therapeutic agents.
Advanced Leukemia Research
The investigator studies Chronic Myelomonocytic Leukemia (CMML) and its treatment, with particular attention to higher-risk cases. Their research includes evaluation of targeted therapies in combination with established treatments.
- Higher-risk CMML
- Targeted therapy combinations
- Treatment of therapy-naïve patients
Their research addresses the needs of patients with advanced hematologic disorders requiring innovative therapeutic solutions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.